Atea Pharmaceuticals
AVIR
126 hedge funds and large institutions have $327M invested in Atea Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 50 increasing their positions, 34 reducing their positions, and 15 closing their positions.
2,376% more call options, than puts
Call options by funds: $13.4M | Put options by funds: $540K
47% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 34
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
0.06% less ownership
Funds ownership: 69.07% → 69.01% (-0.06%)
1% less funds holding
Funds holding: 127 → 126 (-1)
19% less capital invested
Capital invested by funds: $406M → $327M (-$79.2M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.55M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.09M |
| 3 |
ABG
Ally Bridge Group
New York
|
+$2.76M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.74M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$1.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$8.03M |
| 2 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$7.66M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
-$1.88M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.8M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.19M |
AVIR Hedge Fund Activity: Q3 2022 in Review
126 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q3 2022, worth a combined $327M — down 19% from $406M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new AVIR positions and 15 closed out — a net gain of 1 holder — while 50 added to existing stakes and 34 trimmed.
The largest buyer was BlackRock, adding an estimated $3.55M. The largest seller was Balyasny Asset Management, cutting an estimated $8.03M.
- 126 institutional investors held Atea Pharmaceuticals (AVIR) as of Q3 2022, down from 127 in Q2 2022.
- Funds reported $327M of Atea Pharmaceuticals stock for Q3 2022, down 19% quarter-over-quarter.
- 16 funds opened new Atea Pharmaceuticals positions in Q3 2022 and 15 closed out, a net change of +1 holder.
- The largest Atea Pharmaceuticals buyer in Q3 2022 was BlackRock, an estimated $3.55M added.
- The largest Atea Pharmaceuticals seller in Q3 2022 was Balyasny Asset Management, an estimated $8.03M sold.
Based on aggregated 13F filings for Q3 2022.